Phase 3 trial results support toripalimab plus chemotherapy as a first-line treatment option for patients with ES-SCLC, researchers say.

Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.

Male sex was also shown to be an independent risk factor for longer hospital stays and increased hospitalization costs at ...

Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.

Lung cancer is the top cause of cancer-related deaths globally, more prevalent in men, and ranks third among women. Both ...

Non-small cell lung cancer (NSCLC) remains a predominant cause of cancer-related mortality worldwide. In recent years, immune checkpoint inhibitors (ICIs) have emerged as a transformative therapeutic ...

Lung cancer is the leading cause of cancer deaths in America, and catching it early is vital. That’s exactly what a low-dose ...

Content by Intermountain Health Regional Communications. Did you know that raising awareness and encouraging screening can ...

6 Around 80-85% of all lung cancers are non-small cell lung cancer (NSCLC) 7, and most cases of lung cancer in non-smokers ...

These tiny particles are small enough to be inhaled deeply into the lungs, where they can trigger mutations. Upon entering ...

Immutep's American depositary receipts jumped after the company reported positive data from a trial evaluating its drug Efti in combination with Merck's therapy Keytruda for treating non-small cell ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...